



**深圳市海王英特龍生物技術股份有限公司**  
**SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED\***  
*(a joint stock limited company incorporated in the People's Republic of China)*  
**(Stock Code: 8329)**

**FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING**

I/We <sup>(note i)</sup> \_\_\_\_\_ of \_\_\_\_\_ being the registered holder(s) of <sup>(note ii)</sup> \_\_\_\_\_ H shares (the “H Shares”)/domestic shares (the “Domestic Shares”) of RMB0.10 each in the share capital of Shenzhen Neptunus Interlong Bio-technique Company Limited (the “Company”), **HEREBY APPOINT** <sup>(note iii)</sup> \_\_\_\_\_ of \_\_\_\_\_ or failing him, the Chairman of the meeting as my/our proxy/our proxies in respect of <sup>(note v)</sup> \_\_\_\_\_ H Shares/Domestic Shares in the share capital of the Company held by me/us and on my/our behalf to attend and vote for me/us at the extraordinary general meeting of the Company (the “Meeting”) to be held at 10:00 a.m. on Tuesday, 31 December 2024 at Meeting Room, 24th Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Nanshan District, Shenzhen, Guangdong Province, the People's Republic of China (the “PRC”) (and at any adjournment thereof), for the purpose of considering and, if thought fit, passing, with or without modifications, the resolutions set out in the notice convening the Meeting and at such Meeting (and at any adjournment thereof) to vote for me/us and in my/our names(s) in respect of the resolutions as hereunder indicated.

Please make a mark (✓) in the appropriate boxes to indicate how you wish your vote(s) to be cast on a poll.

AS ORDINARY RESOLUTIONS		FOR <sup>(note vi)</sup>	AGAINST <sup>(note vi)</sup>
1.	<p><b>“THAT</b></p> <p>(a) the form and substance of the supplemental agreement (the “<b>2023 Supplemental Yidianyao Distribution Agreement</b>”) dated 15 November 2024 entered into between the Company and 深圳市海王易點藥醫藥有限公司 (Shenzhen Neptunus Yidianyao Pharmaceutical Company Limited*) (a copy of the 2023 Supplemental Yidianyao Distribution Agreement has been produced to the meeting and marked “A” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;</p> <p>(b) the proposed revision of the Existing Annual Cap to the Revised Annual Cap under the 2023 Supplemental Yidianyao Distribution Agreement for the year ending 31 December 2024 be and is hereby confirmed and approved; and</p> <p>(c) any one director of the Company (the “<b>Director</b>”) be and are hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Director may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the 2023 Supplemental Yidianyao Distribution Agreement or any transactions contemplated thereunder and to agree to such variation, amendments or waiver or matters relating thereto (including any variation, amendments or waiver of such documents, which are not fundamentally different from those as provided under the 2023 Supplemental Yidianyao Distribution Agreement) as are, in the opinion of the Director, in the interest of the Company and its shareholders as a whole.”</p>		
2.	<p><b>“THAT</b></p> <p>(a) the form and substance of the distribution agreement (the “<b>2024 Yidianyao Distribution Agreement</b>”) dated 15 November 2024 entered into between the Company and 深圳市海王易點藥醫藥有限公司 (Shenzhen Neptunus Yidianyao Pharmaceutical Company Limited*) (a copy of the 2024 Yidianyao Distribution Agreement has been produced to the meeting and marked “B” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;</p> <p>(b) the proposed sales caps under the 2024 Yidianyao Distribution Agreement for each of the three years ending 31 December 2025, 2026 and 2027 be and is hereby confirmed and approved; and</p> <p>(c) any one Director be and are hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Director may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the 2024 Yidianyao Distribution Agreement or any transactions contemplated thereunder and to agree to such variation, amendments or waiver or matters relating thereto (including any variation, amendments or waiver of such documents, which are not fundamentally different from those as provided under the 2024 Yidianyao Distribution Agreement) as are, in the opinion of the Director, in the interest of the Company and its shareholders as a whole.”</p>		

AS ORDINARY RESOLUTIONS		FOR <i>(note vi)</i>	AGAINST <i>(note vi)</i>
3.	<p><b>“THAT</b></p> <p>(a) the form and substance of the distribution agreement (the <b>“2024 Pharmaceutical Distribution Agreement”</b>) dated 15 November 2024 entered into between 深圳海王長健醫藥有限公司 (Shenzhen Neptunus Changjian Pharmaceutical Company Limited*) and 深圳海王藥業有限公司 (Shenzhen Neptunus Pharmaceutical Company Limited*) (a copy of the 2024 Pharmaceutical Distribution Agreement has been produced to the meeting and marked “C” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;</p> <p>(b) the proposed purchase caps under the 2024 Pharmaceutical Distribution Agreement for each of the three years ending 31 December 2025, 2026 and 2027 be and is hereby confirmed and approved; and</p> <p>(c) any one Director be and are hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Director may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the 2024 Pharmaceutical Distribution Agreement or any transactions contemplated thereunder and to agree to such variation, amendments or waiver or matters relating thereto (including any variation, amendments or waiver of such documents, which are not fundamentally different from those as provided under the 2024 Pharmaceutical Distribution Agreement) as are, in the opinion of the Director, in the interest of the Company and its shareholders as a whole.”</p>		

Signature(s) *(note vii)* \_\_\_\_\_

Dated this: \_\_\_\_\_ day of \_\_\_\_\_

- i. Please insert the full name(s) and address(es) (as shown in the register of members of the Company) in **BLOCK CAPITALS**. Only one of the joint holders of the Share(s) needs to sign (but see note viii below).
- ii. Please insert the number of all the Domestic Shares or H Shares registered in your name(s).
- iii. A member entitled to attend and vote at the Meeting is entitled to appoint in writing one or more proxies to attend and vote on his behalf. Please insert the name and address of the proxy desired. **IF NO NAME IS INSERTED, THE CHAIRMAN OF THE MEETING WILL ACT AS YOUR PROXY.** The proxy need not be a member of the Company but must attend the Meeting in person to represent you.
- iv. **ANY ALTERATION MADE TO THIS FORM OF PROXY MUST BE INITIALLED BY THE PERSON WHO SIGNS IT.**
- v. Please indicate clearly the number of the Domestic Shares or H Shares registered in your name(s) in respect of which the proxy is so appointed. If no such number is inserted, the proxy is deemed to be appointed in respect of all the Domestic Shares or H Shares registered in your name(s).
- vi. **IMPORTANT: IF YOU WISH TO VOTE FOR A RESOLUTION, PLEASE TICK THE APPROPRIATE BOX MARKED “FOR”. IF YOU WISH TO VOTE AGAINST A RESOLUTION, PLEASE TICK THE APPROPRIATE BOX MARKED “AGAINST”.** If you wish to vote only part of the number of the Domestic Shares or H Shares in respect of which the proxy is so appointed, please state the exact number of the Domestic Shares or H Shares in lieu of ticking in the relevant box. Failure to tick or state the exact number of the Domestic Shares or H Shares in any box will entitle your proxy to cast his votes at his discretion.
- vii. This form of proxy must be signed by you or your attorney duly authorised in writing or, if you are a corporation, must either be executed under seal or under the hand of a director, attorney or other person duly authorised. If this form of proxy is signed by your attorney, the power of attorney or other document of authorisation must be notarised.
- viii. Where there are joint holders of any Domestic Shares or H Shares, any one of such persons may vote at the Meeting either personally, or by proxy, in respect of such Domestic Shares or H Shares as if he was solely entitled thereof, and if more than one of such joint holders are present at the Meeting personally or by proxy, that one of the said persons so present whose name stands first on the register of members of the Company shall alone be entitled to vote.
- ix. In order to be valid, this form of proxy together with a power of attorney or other authority (if any) under which it is signed or the notarised copy of such power of attorney or authority must be deposited, in the case of holders of the H Shares, at the Company’s H share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, and in the case of holders of the Domestic Shares, at the registered office of the Company at Suite 1702, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Maling Community, Yuehai Sub-district, Nanshan District, Shenzhen, the PRC no later than 24 hours before the time appointed for the holding of the Meeting (i.e. not later than 10:00 a.m. on Monday, 30 December 2024) or any adjournment thereof (as the case may be).
- x. Completion and return of this form will not preclude you from attending and voting at the Meeting or the adjourned Meeting if you so wish. If you attend and vote at the Meeting or the adjourned Meeting, the authority of your proxy will be revoked.
- xi. References to time and dates in this form of proxy are to Hong Kong time and dates.

#### PERSONAL INFORMATION COLLECTION STATEMENT

Your supply of your and your proxy’s (or proxies’) name(s) and address(es) is on a voluntary basis for the purpose of processing your request for the appointment of a proxy (or proxies) and your voting instructions for the Meeting of the Company (the “Purposes”). We may transfer your and your proxy’s (or proxies’) name(s) and address(es) to our agent, contractor, or third party service provider who provides administrative, computer and other services to us and to such parties who are authorized by law to request the information or are otherwise relevant for the Purposes and need to receive the information. Your and your proxy’s (or proxies’) name(s) and address(es) will be retained for such period as may be necessary to fulfil the Purposes. Request for access to and/or correction of the relevant personal data can be made in accordance with provisions of the Personal Data (Privacy) Ordinance (Cap. 486) and any such request should be in writing by mail to the Company at the above address.

\* For identification purpose only